TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
ATYR

aTyr Pharma, Inc.

Healthcare · Biotechnology

6.30$ +27.3% vs. previous close Closing price · As of: Nov 2, 2026

Ownership

Ownership Structure

Who owns aTyr Pharma, Inc. (ATYR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.6% of the shares are freely tradable; institutional investors hold 48.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 48.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 99.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 13.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 98Mio.

Largest Shareholders

Institutions

Institutions ATYR
Name Stake (%) Shares Change (%) Date
Federated Hermes Inc 8.68 8,509,678 -19.0 06/30/2026
Vanguard Capital Management, LLC 3.88 3,808,091 -0.1 06/30/2026
Kalehua Capital Management LLC 3.65 3,576,334 +0.0 06/30/2026
GSA Capital Partners LLP 3.52 3,454,863 +105.1 06/30/2026
AQR Capital Management LLC 2.66 2,610,548 +426.3 06/30/2026
FMR Inc 2.52 2,471,418 -83.2 06/30/2026
BlackRock Inc 1.86 1,827,332 -71.6 06/30/2026

Funds

Funds ATYR
Name Stake (%) Shares Change (%) Date
Federated Hermes Kaufmann R 4.45 4,367,290 -21.8 06/30/2026
Federated Hermes Kaufmann Small Cap A 4.14 4,061,288 -15.5 06/30/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.70 2,650,788 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?